Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells

7 Apr 2018

Abstract excerpt

Kinase inhibitors are efficient in reducing cancer cell viability in cases where malignant cells present a dependency or addiction to the targeted kinase [ 1 ]. Genetic alterations can cause constitutive activation of pro-survival and proliferative pathways and often determine the extent by which cancer cells respond to targeted drugs [ 2 , 3 ]. However, other biochemical events, not directly linked to genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29626197
DOI: 10.1038/s41375-018-0032-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsPMID 29626197Read ↗

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read ↗

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLSemantic proximity Read ↗

Proteomic Characterization of Acute Myeloid Leukemia for Precision MedicineSemantic proximity Read ↗

Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor ScreeningSemantic proximity Read ↗

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaSemantic proximity Read ↗

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patientsSemantic proximity Read ↗

Phosphoproteomics identifies determinants of PAK inhibitor sensitivity in leukaemia cellsSemantic proximity Read ↗

Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.Semantic proximity Read ↗

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.Semantic proximity Read ↗

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesSemantic proximity Read ↗

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.Semantic proximity Read ↗

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.